SIGA Technologies Inc. (SIGA) is a pharmaceutical company that specializes in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is publicly traded under the ticker "SIGA" on the NASDAQ exchange. Since its inception in the mid-1990s, SIGA Technologies has been dedicated to improving health security, both domestically and globally, through the introduction of innovative therapeutics.
The primary focus of SIGA Technologies is creating antiviral therapies for high-consequence, viral infectious diseases. This unerring dedication to combating biothreats has shaped the company's rigorous approach to research and development, thus making them a leader in their field.
The cornerstone of SIGA’s product pipeline is TPOXX® (tecovirimat), the first-ever drug with an indication for the treatment of smallpox. The U.S. Food and Drug Administration (FDA) approved TPOXX in 2018, marking a significant milestone in global health security. Since smallpox is considered a potential bioterrorism threat, TPOXX's introduction has been highly commendable and well-received within the public health sector.
Its commitment to medical advancement does not stop there. SIGA Technologies is also actively involved in conducting multiple pre-clinical programs aimed at addressing other biothreats. Through collaboration with governmental, non-governmental, and commercial entities, SIGA aims to combat emerging viral diseases and potential bioterrorism threats.
In addition to their dedication to public health and safety, SIGA Technologies is committed to creating value for its shareholders. Their strategic partnerships with entities such as the Biomedical Advanced Research and Development Authority and U.S. Department of Defense underscore their ability to deliver on shared objectives.
On the corporate side, SIGA Technologies boasts a diverse workforce and a leadership team that combines broad industry knowledge with a history of innovative solutions. Its guiding principles emphasize ethical business practices and integrity in all aspects of their business, from research to manufacturing.
In conclusion, SIGA Technologies is a company that operates at the forefront of health security, addressing critical unmet medical needs by utilizing its expertise in drug discovery, development, and commercialization. By addressing biothreats and ensuring its commitment to shareholders and ethics, SIGA Technologies continues to underline its pivotal role within the global healthcare landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
SIGA Technologies reported $38 million in Q2 2026 product revenues, driven by U.S. government IV TPOXX deliveries and international sales, fulfilling its 2018 contract obligations and engaging in new procurement discussions. The company is expanding its global footprint through a distribution agreement with Hikma for the MENA region and advancing its post-exposure prophylaxis and pediatric programs, with a strong financial position of $118 million in cash. Management emphasized ongoing government partnerships and international market growth as key strategies for addressing smallpox preparedness.
Bank of America Corp DE recently acquired 427,275 shares of Siga Technologies Inc. (NASDAQ:SIGA), valued at approximately $1.56 million, making up about 0.59% of the company. Other institutional investors like BlackRock and Dimensional Fund Advisors also increased their stakes, with institutions and hedge funds collectively owning 55.4% of SIGA. Despite the institutional interest, the company's shares opened at $3.35, significantly below its 52-week high, and MarketBeat reports an average analyst rating of “Sell.”
SIGA Technologies reported a significant drop in revenue and profits for the recent quarter and first half of the year compared to the previous year, with net income falling by 65%. This decline is largely attributed to the completion of a major government contract (19C) for TPOXX sales. Despite the downturn, the company remained profitable and issued a special cash dividend, while also expanding international and alternative stockpile orders.
BlackRock Inc. has invested $15.24 million in Siga Technologies Inc., acquiring 4.19 million shares, representing a 5.84% stake. Despite this new investment, analyst sentiment for Siga Technologies remains negative, with the stock downgraded to "sell" and a consensus "Sell" rating. The company reported quarterly revenue of $41 million and earnings per share of $0.17, but continues to show negative profitability metrics.
Siga Technologies (NASDAQ:SIGA) shares rose 2.6% in Monday trading, but analyst sentiment remains negative with a "Sell" rating. The company reported quarterly EPS of $0.17 on $41 million revenue, though profitability was weak. Institutional investors have recently adjusted their holdings in the specialty pharmaceutical company.